구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Erbitux |
Overview Company | Eli Lilly / Merck KGaA |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Cancer |
Overview Indication | Head and Neck Cancer Squamous Cell |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel strategies of biotherapeutics |
Positioning Known limitation | resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models |
MoA Mechanism | targeting the epidermal growth factor receptor |
MoA Biomarker | EGFR SR could be established with high |
PK/PD Half-life | 5.2 h |
PK/PD Species | Pig |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Pig |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux ® ) in Healthy Chinese Male Subjects.. This study aimed to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity of the proposed A140 with those of cetuximab (Erbitux ® ) in healthy Chinese male subjects. We conducted a randomized, single-dose, double-b… |
Clinical Safety signal | A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux ® ) in Healthy Chinese Male Subjects.. This study aimed to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity of the proposed A140 with those of cetuximab (Erbitux ® ) in healthy Chinese male subjects. We conducted a randomized, single-dose, double-b… |
Clinical Selected reported efficacy | ORR 52.2% |
Clinical Reported ORR | 52.2% |
Clinical Result source | ClinicalTrials.gov NCT00527111 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00527111 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Erbitux |
Overview Company | Eli Lilly / Merck KGaA |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Cancer |
Overview Indication | Head and Neck Cancer Squamous Cell |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel strategies of biotherapeutics |
Positioning Known limitation | resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models |
MoA Mechanism | targeting the epidermal growth factor receptor |
MoA Biomarker | EGFR SR could be established with high |
PK/PD Half-life | 5.2 h |
PK/PD Species | Pig |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Pig |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux ® ) in Healthy Chinese Male Subjects.. This study aimed to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity of the proposed A140 with those of cetuximab (Erbitux ® ) in healthy Chinese male subjects. We conducted a randomized, single-dose, double-b… |
Clinical Safety signal | A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of A140 Injection and Cetuximab (Erbitux ® ) in Healthy Chinese Male Subjects.. This study aimed to compare the pharmacokinetic (PK) profiles, safety, and immunogenicity of the proposed A140 with those of cetuximab (Erbitux ® ) in healthy Chinese male subjects. We conducted a randomized, single-dose, double-b… |
Clinical Selected reported efficacy | ORR 52.2% |
Clinical Reported ORR | 52.2% |
Clinical Result source | ClinicalTrials.gov NCT00527111 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00527111 |
추천 비교
추천 비교